Eli Lilly will file for approval of retatrutide obesity drug in 2027
The Eli Lilly logo appears on the company’s office in San Diego, California, Nov. 21, 2025. Mike Blake | Reuters Eli Lilly on Thursday said it will file for approval of its next-generation obesity drug in the first quarter of 2027, as the treatment succeeds in two more late-stage trials. The pharmaceutical giant previously said...






